New drugs in multiple myeloma - Role of carfilzomib and pomalidomide

Wspolczesna Onkologia

Volumn 18, Issue 1, 2014, Pages 17-21

  Jurczyszyn, Artur ^a   Legieć, Wojciech ^b   Helbig, Grzegorz ^c   Hus, Marek ^b   Kyrcz Krzemień, Sławomira ^c   Skotnicki, Aleksander B ^d  

^a UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Carfilzomib; Multiple myeloma; Pomalidomide; Treatment

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; NEW DRUG; POMALIDOMIDE; PREDNISONE; THALIDOMIDE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LUNG INJURY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84898455706     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.40175     Document Type: Review

References (32)

1. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012: 120: 2817-25.
2. Dimopoulos MA, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013; 13: 235-7.
3. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
4. Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and highrisk cytogenetics receiving single-agent carfilzomib in the PX-171- 003-A1 study. Leukemia 2013; 27: 2351-6.
5. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-70.
6. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/ or refractory multiple myeloma who have been previously treated with bortezomib. Br J Hematol 2012; 158: 739-48.
7. Niesvizky R, Vij R, Martin T, et al. Carfilzomib pharmacokinetics, safety and activity in patients with relapsed or refractory multiple myeloma and renal dysfunction: final results (abstract no. 0890). Haematologica 2011; 96 Suppl. 2: 370-1.
8. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27: 1707-14.
9. US FDA. NDA 202,714, Onyx Pharmaceuticals, Inc., Proposed Trade Name: Kyprolis (Carfilzomib for Injection), Briefing Document, ODAC Meeting Date: 20 June 2012, Submission Date: 17 May 2012, Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/OncologicDrugs-AdvisoryCommittee/UCM308565.pdf.
10. US FDA. KYPROLIS™ (carfilzomib) for Injection, for intravenous use Initial U.S. Approval: 2012. Prescription information. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202714lbl.pdf.
11. Sonneveld P, Asselbergs E, Zweegman S, et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is a highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (mm) who are transplant candidates. Paper presented at: 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
12. Mikhael JR, Reeder CB, Libby EN III, et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. Paper presented at: 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
13. Palumbo A, Bringhen S, Villani O, et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients. Paper presented at: 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
14. Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Paper presented at: 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
15. Alsina M, Baz R, Shain KH, et al. Updated results of phase II study of cyclophosphamide (Cy), bortezomib (Bz), pegylated doxorubicin (DOX), and dexamethasone (dex),(CVDD), in patients with newly diagnosed myeloma: an effective induction regimen for high risk disease. Poster presented at: 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
16. Cavo M. A third-generation IMID for MM. Blood 2011; 118: 2931-2.
17. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013; 54: 683-7.
18. Schuster S, Kortuem K, Zhu Y, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 194.
19. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-76.
20. Streetly M, Hunt BJ, Parmar K, et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005; 74: 293-6.
21. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41-51.
22. Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenbalidomide and bortezomib. Blood 2013; 121: 1961-7.
23. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-14.
24. Lacy MQ, Haymann SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934-9.
25. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomde: comparison of 2 dosing strategies In dual-refractory disease. Blood 2011; 118: 2970-5.
26. Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus lowdose dexamethasone (Pom/Dex) in relapsed myeloma: long term follow up and factors predicting outcome in 345 patients. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 201.
27. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide- refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013; 121: 1968-75.
28. Dimopoulos MA, Lacy MQ, Moreau P, et al. Pomalidomide in combination with low0dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 6.
29. Palumbo A, Larocca A, Carella AM, et al. A phase I/II study of pomalidomide- cyclophosphamide-prednisone (PCP) in patients with multiple myeloma relapsed/refractory to lenalidomide. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 446.
30. Tomer MM, Rodriguez M, Shah M, et al. ClaPD (clarithromycin/ [Biaxin], pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 77
31. Geyer HL, Viggiano RW, Lacy MQ, et al. Acute lung toxicity related to pomalidomide. Chest 2011; 140: 529-33.
32. Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (Pom) with low-dose dexamethasone (LoDex) in patients with relapsed and refractory multiple myeloma who have received prior therapy with lenalidomide and bortezomib: updated phase 2 results and age subgroup analysis. Blood (American Society of Hematology Annual Meeting) 2012; 120: abstract 450.